Towards a deeper understanding of complex interactions governing the immune response

Next-generation sequencing (NGS) may help to discover factors that can impact the immune system’s ability to target tumors

Tumor Microenvironment Analysis

Tumor tissues vary considerably in their microenvironment, and the existence of other cell types can influence the ability of the immune system to infiltrate and attack tumor cells. As promising new therapies evolve, there is an increasing need to identify cancer immunotherapy biomarkers to guide their appropriate application.

NGS can provide careful analysis of the cancer genome, and efficiently assess the tumor microenvironment as a real-time, highly sensitive monitor of immune marker expression in response to tumor growth or treatment. NGS analysis can be used to characterize the immune cell repertoire, identify various cell populations in the microenvironment, and comprehensively quantify gene expression of thousands of targets simultaneously.

Featured Cancer Immunotherapy Research Publications

High-throughput sequencing has shown remarkable utility in cancer and immunology research, as well as in the development of individualized immunotherapy.

Read Publication Summaries

RNA analysis may help to identify aspects of the tumor microenvironment that can influence the effectiveness of checkpoint immunotherapies, such as inductive and inhibitory cytokines, and local recruitment of other cell types that can inhibit the T-cell response.

Learn More About Cancer RNA-Seq

Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. NGS and microarray technologies can detect altered methylation and other epigenetic patterns in cancer.

Learn More About Cancer Epigenetics

Featured Tumor Microenvironment & Immunotherapy Research

 
The Tumor Microenvironment
Exploring the Tumor Microenvironment

Single-cell sequencing proves invaluable in detecting intracellular communication in tumors.

Read Interview
T cells on a tumor
Immunotherapies Using Tumor-Specific HLA Ligands

RNA-Seq and HLA typing using NGS are powering the Immatics target discovery platform.

Read Interview
Tumor cell and immune system
Cancer and Immune System Research Review

High-throughput sequencing has shown remarkable utility in cancer and immunology research, as well as in the development of individualized immunotherapy.

Read Review
Harnessing the Tumor Microenvironment
Harnessing the Tumor Microenvironment

In this webinar, cancer research and immuno-oncology leaders explore new approaches for assessing the potential of transforming and harnessing the tumor immune microenvironment for therapeutic benefit.

View Webinar
Spatial Analysis of the Tumor Microenvironment
Illumina and NanoString Technologies

Register today to discover the latest news on how Illumina and NanoString help to deliver on the promise of spatial biology.

View Webinar

Cancer researchers need simple-to-use bioinformatics applications to gain insights from tumor microenvironment studies and other complex genomic data. BaseSpace Cohort Analyzer allows biologists and researchers to make important discoveries without specialized bioinformatics skills. The retrospective analysis of clinical trial data can help inform future cancer research and drug development programs.

Learn more about BaseSpace Cohort Analyzer and BaseSpace Correlation Engine.

Informatics Applications for Immuno-oncology Research Using NGS

Improved informatics tools enable tumor microenvironment analysis and neoantigen discovery.

View Tech Note

Illumina offers several library preparation and sequencing options with access to data analysis options for tumor microenvironment analysis. Streamlined workflows and flexible kit configurations accommodate multiple study designs.

Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*

Click on the below to view products for each workflow step.

Nextera Flex for Enrichment

Nextera Flex for Enrichment uses a fast, user-friendly workflow. On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time.

TruSeq DNA Exome

TruSeq DNA Exome is a cost-effective library preparation and exome enrichment solution.

TruSeq RNA Exome

The TruSeq RNA Exome library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.

Illumina Bio-Rad ® SureCell™ WTA 3′ Library Prep Kit for the ddSEQ™ System

Transcriptome profiling of hundreds to tens of thousands of single cells in a single experiment.

TruSight Oncology 500

Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.

NextSeq 550 System

Flexible configurations that support up to 12 exomes per run.

NovaSeq 6000 System

Flexibility and unprecedented throughput for virtually any genome, sequencing method, and scale of project.

BaseSpace Sequence Hub Apps

BaseSpace Sequence Hub offers a wide variety of NGS data analysis apps. Use the RNA-Seq filter to find apps for analyzing RNA sequencing data.

BaseSpace Enrichment App

Uses the Isaac Genome Alignment Software and the Isaac Variant Caller for exome data analysis.

Exclusive Offer for TruSight Oncology 500

Purchase the TruSight Oncology 500 assay for the first time and receive an exclusive limited time offer.

Learn More
Exclusive Offer for TruSight Oncology 500
Genomic Technologies for Cancer Research
Genomic Technologies for Cancer Research

Learn the numerous ways that genomic technologies can be applied to tumor biology.

Access PDF
Participant Stratification in Immuno-Oncology
Stratifying Subjects for Immunotherapy Research

Genomics scientists discuss how NGS can help stratify subjects for clinical research.

View Webinar
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up

*Data calculations on file, Illumina, Inc, 2015.